Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Kiplinger1mon
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
"We are very encouraged by the subcutaneous Phase 1b/2a results for Amycretin in people living with overweight or obesity," said Martin Lange, executive vice president for Development at Novo Nordisk.
Business Insider28d
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
"We're examining whether Novo Nordisk may have intentionally misled investors about the trial's design and potential tolerability issues," said Reed Kathrein, the Hagens Berman partner leading the ...